Skip to main content

Day: April 8, 2025

Notice on the Convened Ordinary General Meeting of Shareholders of Vilkyškių pieninė AB

AB Vilkyškių pieninė (hereinafter referred to as the Company), company code 277160980, by the initiative and decision of the Board, convenes the Ordinary General Meeting of Shareholders on 29 April 2025, at 9:00 AM at the Company’s registered seat address at P. Lukošaičio st. 14, Vilkyškiai, LT-99254 Pagėgiai municipality. Shareholder registration will begin at 8:00 AM and will end at 8:50 AM. AGENDA OF THE ORDINARY GENERAL MEETING OF SHAREHOLDERS:Regarding the independent auditor’s report on the Company’s 2024 separated and consolidated financial statements and the limited assurance auditor’s report on the consolidated Sustainability Statement. Regarding the Supervisory Board’s feedback and proposals. Regarding agreement of the Company’s 2024 consolidated and separated annual management report. Regarding approval...

Continue reading

Nexus Industrial REIT Announces the Sale of Legacy Retail and Office Buildings and Leasing Update

OAKVILLE, Ontario, April 08, 2025 (GLOBE NEWSWIRE) — Nexus Industrial REIT (“Nexus” or the “REIT”) (TSX: NXR.UN) is pleased to announce the sale of its 50% ownership interest in 15 retail buildings located in Quebec for $47 million and one office building also located in Quebec for $4 million, representing cap rates on in-place rents of 6.8% and 9.5% respectively (together, the “Properties”). The REIT intends to use the net proceeds from the dispositions to repay existing indebtedness on its credit facility and to fund development projects. “These sales mark the substantial completion of our transition to a pure-play, Canada-focused industrial REIT” said Kelly Hanczyk, CEO of Nexus Industrial REIT. “Over the past five years we have successfully re-focused and grown Nexus to be a scale pure-play industrial REIT, with...

Continue reading

RCI Banque: ‘’Consolidated Financial Statements as at December 31th 2024’’ is now available”

April 8th, 2025 RCI Banque: ‘’Consolidated Financial Statements as at December 31th 2024’’ is now available.” The RCI Banque group ‘’Consolidated Financial Statements as at December 31th 2024’’ is now available on the Mobilize Financial Services website www.mobilize-fs.comAttachmentsRCI_Banque_-_RCC_2024 ENPress Release – Consolidated Financial Statements as at 31 december 2024

Continue reading

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) —  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference. The Company provided an update on patient demand metrics that was in line with guidance from its full-year results announcement on March 3, 2025. It also addressed questions related to the recent developments in United States tariff policy and the potential impact on the biopharmaceutical sector, including Avadel. Specifically:In Q1 2025 patient demand metrics for LUMRYZ™, Avadel’s innovative narcolepsy medication with a market potential of a billion dollars in peak annual sales, all improved versus Q4 2024. These improvements include patient enrollments, patient starts, persistency...

Continue reading

Costamare Inc. Announces Details for the Upcoming Costamare Bulkers Holdings Limited Virtual Analyst and Investor Day

MONACO, April 08, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (NYSE:CMRE) (the “Company”) announces Conference Call Details for the virtual Analyst and Investor Day that the incoming management team of Costamare Bulkers Holdings Limited (“Costamare Bulkers”) will host on Wednesday April 9, 2025, at 9:00 a.m. Eastern Daylight Time. Costamare Bulkers is the new company that will hold Costamare Inc.’s owned dry bulk vessels and the CBI operating platform upon completion of Costamare Inc.’s previously announced spin-off of its dry bulk business. Conference Call Details: On Wednesday, April 9, 2025 at 9:00 a.m. ET, the incoming management team of Costamare Bulkers will hold a conference call to discuss Costamare Bulkers’ core business and operations, investment highlights, and strategic outlook, followed by a Q&A session. Participants...

Continue reading

Eloro Resources Announces Closing of Brokered Private Placement for Gross Proceeds of C$5.3 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, April 08, 2025 (GLOBE NEWSWIRE) — Eloro Resources Ltd. (TSX: ELO; OTCQX: ELRRF; FSE: P2QM) (“Eloro” or the “Company”) is pleased to announce the closing of its previously announced best efforts private placement (the “Offering“) for aggregate gross proceeds of C$5,275,101, which includes the partial exercise of the agents’ option for gross proceeds of C$275,101. Under the Offering, the Company sold an aggregate of 5,552,738 units of the Company (the “Units”) at a price of C$0.95 per Unit (the “Offering Price”). Each Unit consists of one common share of the Company (each, a “Unit Share”) and one half of one common share...

Continue reading

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MS Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression...

Continue reading

Societe Generale announces results of the offer to purchase certain of its debt securities

SOCIETE GENERALE ANNOUNCES RESULTS OF THE OFFER TO PURCHASE CERTAIN OF ITS DEBT SECURITIES  Press release Paris, April 8, 2025 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE OR TO WHOM IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. Further to the announcement on April 1, 2025 of the launch of an offer to purchase for cash (the “Offer”) any and all of its outstanding Undated Deeply Subordinated Resettable Interest Rate Notes referred to below (the “Notes”), Societe Generale today announces the results of the Offer. The expiration time for the Offer was 5:00 p.m. (New York City time) on April 7, 2025. According to information provided by the Tender and Information Agent for the Offer, $710,342,000 aggregate principal amount of the Notes were validly...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.